---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-025725"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2024-07-01T23:59:59+00:00"
generated_at: "2026-05-31T23:54:54.815363+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cassava discloses potential unblinding in Phase 2b study; collaborator indicted by DOJ

## Summary
- DOJ indicted Dr. Wang for allegedly causing false statements to NIH about simufilam; company terminated his consulting.
- Internal investigation found senior employee may have unblinded Dr. Wang to some Phase 2b participants before bioanalysis.
- Reported Phase 2b CANTAB analysis excluded ~42% of subjects for episodic memory; results reflect smaller analysis set.
- Phase 3 trials fully enrolled (~1,900 patients), remain blinded; independent firms will handle bioanalysis.

## SEC filing metadata
- accession: 0001493152-24-025725
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2024-07-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000149315224025725/0001493152-24-025725-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000149315224025725/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-025725
- JSON: https://secwatch.observer/filing/0001493152-24-025725.json
- Plain text: https://secwatch.observer/filing/0001493152-24-025725.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.